Long-term outcomes of penile squamous cell carcinoma in men age ≤50 years old compared with men >50 years old from a single tertiary referral centre: a propensity score matched analysis.
Journal
International journal of impotence research
ISSN: 1476-5489
Titre abrégé: Int J Impot Res
Pays: England
ID NLM: 9007383
Informations de publication
Date de publication:
29 Feb 2024
29 Feb 2024
Historique:
received:
10
11
2023
accepted:
09
02
2024
revised:
23
01
2024
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
29
2
2024
Statut:
aheadofprint
Résumé
Penile cancer (PeCa) is rare, and the oncological outcomes in younger men are unclear. We aimed to analyse and compare oncological outcomes of men age ≤50 years (y) and >50 years with PeCa. A retrospective analysis of men ≤50 y with penile squamous cell carcinoma managed at a tertiary centre was performed. A propensity score matched cohort of men >50 y was identified for comparison. Matching was according to tumour, nodal stage and the types of primary surgery. Overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS), and metastasis-free survivals (MFS) were estimated using Kaplan-Meier plots and compared using log-rank tests. Between 2005-2020, 100 men ≤50 y (median (IQR) age, 46 y (40-49)) were identified and matched with 100 men >50 y (median (IQR) age, 65 y (59-73)). 10, 24, 32, 34 men age ≤50 y were diagnosed in 2005-2007, 2008-2012, 2013-2016 and 2017-2020 respectively. Median (IQR) follow-up was 53.5 (18-96) months. OS at 2 years: ≤50 y, 86%>50 y, 80.6%; 5 years: ≤50 y, 78.1%, >50 y, 63.1%; 10 years: ≤50 y, 72.3%, >50 y, 45.6% (p = 0.01). DSS at 2 years: ≤50 y, 87.2%>50 y, 87.8%; 5 years: ≤50 y, 80.9%>50 y, 78.2%; 10 years: ≤50 y, 78%, >50 y, 70.9% (p = 0.74). RFS was 93.1% in the ≤50 y group (vs. >50 y, 96.5%) at 2 year, and 90% (vs. >50 y, 88.5%) at 5 years, p = 0.81. Within the ≤50 y group, 2 years and 5 years MFS was 93% (vs. >50 y, 96.5%), and 89.5% (vs. >50 y, 92.7%) respectively, (p = 0.40). There were no statistical significance in DFS, RFS and MFS in men age ≤50 y and >50 y. PeCa in younger patients is fatal, public awareness and patient education are crucial for early detection and management.
Identifiants
pubmed: 38424353
doi: 10.1038/s41443-024-00842-5
pii: 10.1038/s41443-024-00842-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Crown.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Cancer Research UK. Penile Cancer Statistics [Internet]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/penile-cancer#:~:text=Penile cancer incidence,year (2016–2018).
Arya M, Li R, Pegler K, Sangar V, Kelly JD, Minhas S, et al. Long-term trends in incidence, survival and mortality of primary penile cancer in England. Cancer Causes Control. 2013;24:2169–76.
doi: 10.1007/s10552-013-0293-y
pubmed: 24101363
Thomas A, Necchi A, Muneer A, Tobias-Machado M, Tran ATH, Van Rompuy A-S, et al. Penile cancer. Nat Rev Dis Prim. 2021;7:11.
doi: 10.1038/s41572-021-00246-5
pubmed: 33574340
Olesen TB, Sand FL, Rasmussen CL, Albieri V, Toft BG, Norrild B, et al. Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 2019;20:145–58.
doi: 10.1016/S1470-2045(18)30682-X
pubmed: 30573285
Audenet F, Sfakianos JP. Psychosocial impact of penile carcinoma. Transl Androl Urol. 2017;6:874–8.
doi: 10.21037/tau.2017.07.24
pubmed: 29184785
pmcid: 5673805
Russell B, Liedberg F, Hagberg O, Ullén A, Söderkvist K, Ströck V, et al. Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer. Scand J Urol. 2022;56:27–33.
doi: 10.1080/21681805.2021.2002399
pubmed: 34775873
Pompe RS, Smith A, Bandini M, Marchioni M, Martel T, Preisser F, et al. Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study. Prostate Cancer Prostatic Dis. 2018;21:71–7.
doi: 10.1038/s41391-017-0006-9
pubmed: 29339806
Darré T, Djiwa T, Kpatcha TM, Padja E, Napo-Koura G, Darre T. Prostate cancers in men under the age of 50: about a series in Togo, Sub-Saharan Africa. BMC Cancer. 2022;22:1341.
doi: 10.1186/s12885-022-10425-6
pubmed: 36544122
pmcid: 9773477
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–9.
doi: 10.1016/j.jclinepi.2007.11.008
Hakenberg OW, Comperat E, Minhas S, Nechhi A, Protzel C, Watkin N. EAU Guidelines on Penile Cancer [Internet]. EAU Guidel. 2022. Available from: https://uroweb.org/guidelines/penile-cancer .
Cakir OO, Schifano N, Venturino L, Pozzi E, Castiglione F, Alnajjar HM, et al. Surgical technique and outcomes following coronal-sparing glans resurfacing for benign and malignant penile lesions. Int J Impot Res. 2022;34:495–500. https://doi.org/10.1038/s41443-021-00452-5 . Epub 2021 Jul 20.
Rodríguez-álvarez MI, Gómez-Urquiza JL, Husein-El Ahmed H, Albendín-García L, Gómez-Salgado J, Cañadas-De la Fuente GA. Prevalence and risk factors of human papillomavirus in male patients: a systematic review and meta-analysis. Int J Environ Res Public Health. 2018;15:2210.
doi: 10.3390/ijerph15102210
pubmed: 30309014
pmcid: 6210641
Mohammed H, Blomquist P, Ogaz D, Duffell S, Furegato M, Checchi M, et al. 100 years of STIs in the UK: a review of national surveillance data. Sex Transm Infect. 2018;94:553–8.
doi: 10.1136/sextrans-2017-053273
pubmed: 29654061
Howell-Jones R, Soldan K, Wetten S, Mesher D, Williams T, Gill ON, et al. Declining genital Warts in young women in england associated with HPV 16/18 vaccination: an ecological study. J Infect Dis. 2013;208:1397–403.
doi: 10.1093/infdis/jit361
pubmed: 24092908
pmcid: 3789575
Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398:2084–92.
doi: 10.1016/S0140-6736(21)02178-4
pubmed: 34741816
Schlenker B, Schneede P. The role of human papilloma virus in penile cancer prevention and new therapeutic agents. Eur Urol Focus. 2019;5:42–5.
doi: 10.1016/j.euf.2018.09.010
pubmed: 30262198
Pang KH, Alnajjar HM, Muneer A. Advances in penile-sparing surgical approaches. Asian J Urol. 2022;9:359–73.
doi: 10.1016/j.ajur.2022.02.005
pubmed: 36381598
pmcid: 9643282
Lindner AK, Schachtner G, Steiner E, Kroiss A, Uprimny C, Steinkohl F, et al. Organ-sparing surgery of penile cancer: higher rate of local recurrence yet no impact on overall survival. World J Urol. 2020;38:417–24.
doi: 10.1007/s00345-019-02793-9
pubmed: 31062123
Pang KH, Muneer A, Alnajjar HM. Glansectomy and reconstruction for penile cancer: a systematic review. Eur Urol Focus. 2022;8:1318–1322.
doi: 10.1016/j.euf.2021.11.008
pubmed: 34903488
Kidd LC, Chaing S, Chipollini J, Giuliano AR, Spiess PE, Sharma P. Relationship between human papillomavirus and penile cancer-implications for prevention and treatment. Transl Androl Urol. 2017;6:791–802.
doi: 10.21037/tau.2017.06.27
pubmed: 29184775
pmcid: 5673821
Veeratterapillay R, Teo L, Asterling S, Greene D. Oncologic outcomes of penile cancer treatment at a UK supraregional center. Urology. 2015;85:1097–103.
doi: 10.1016/j.urology.2014.11.048
pubmed: 25769781
Tang S, Pang KH, Alnajjar HM, Ayres B, Kumar V, Parnham A, et al. Videoendoscopic inguinal lymphadenectomy versus radical open dissection (VELRAD) in patients with male genital cancer: a clinical trial update. Eur Urol Focus. 2023;9:614–6.
doi: 10.1016/j.euf.2023.01.018
pubmed: 36797170
Pérez J, Chavarriaga J, Ortiz A, Orrego P, Rueda S, Quiroga W, et al. Oncological and functional outcomes after organ-sparing plastic reconstructive surgery for penile cancer. Urology. 2020;142:161–5.e1.
doi: 10.1016/j.urology.2020.03.058
pubmed: 32380155
Garaffa G, Raheem AA, Christopher NA, Ralph DJ. Total phallic reconstruction after penile amputation for carcinoma. BJU Int. 2009;104:852–6.
doi: 10.1111/j.1464-410X.2009.08424.x
pubmed: 19239449
Fallara G, Pozzi E, Onur Cakir O, Tandogdu Z, Castiglione F, Salonia A, et al. Diagnostic accuracy of dynamic sentinel lymph node biopsy for penile cancer: a systematic review and Meta-analysis. Eur Urol Focus. 2022;9:500–12.
doi: 10.1016/j.euf.2022.11.018
pubmed: 36470729
Minhas S, Kayes O, Hegarty P, Kumar P, Freeman A, Ralph D. What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int. 2005;96:1040–3.
doi: 10.1111/j.1464-410X.2005.05769.x
pubmed: 16225525